Opendata, web and dolomites

Facer SIGNED

The First Cell Culture Platform that Enables Affordable Cell Therapies at a Large Scale

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Facer project word cloud

Explore the words cloud of the Facer project. It provides you a very rough idea of what is the project "Facer" about.

globally    medical    device    cash    sale    surpass    injected    validation    small    course    local    therapy    2024    once    biopsy    describe    diabetes    performances    expand    gain    trl    platform    innovation    specialised    millions    asks    distributor    incurable    affordable    modified    lower    quality    36    initially    ebitda    marking    investments    cells    perform    scalable    treatments    commercially    conclude    centres    regulatory    patented    infrastructure    successfully    diseases    human    tissue    shown    culture    customer    2018    quantity    hinders    superior    manufacture    barriers    nowadays    approved    turnover    billions    deemed    overcome    patients    curing    possibly    starting    competitor    external    few    launching    thanks    culturing    treating    iterative    market    afford    cancer    life    tackle    first    ce    cell    million    august    blood    principles    facer    autonomous    quantities    approval    therapies    suffer    finalise    500    intervention   

Project "Facer" data sheet

The following table provides information about the project.

Coordinator
AGLARIS LIMITED 

Organization address
address: STEVENAGE BIOSCIENCE CATALYST, F30, GUNNELS WOOD R
city: STEVENAGE
postcode: SG1 2FX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 2˙051˙000 €
 EC max contribution 1˙435˙700 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AGLARIS LIMITED UK (STEVENAGE) coordinator 1˙435˙700.00

Map

 Project objective

Cell therapy has shown promising results for treating and curing a large range of diseases, from cancer to diabetes. The principles of cell therapy are easy to describe: cells (possibly modified) are injected into patients. Cell therapy is now a reality in Europe: in August 2018 the first two treatments for patients with blood cancer were approved; more of them are about to successfully conclude the approval path. What hinders the large-scale uptake of cell therapy is its costs: culturing enough cells of high quality requires specialised personnel and infrastructure, which only a few centres can afford. The market asks for a scalable cell culture platform that can produce large quantities of high quality cells at much lower costs than done nowadays. To address this need, we have developed the Facer – the first fully-autonomous cell culture platform. The Facer can manufacture billions of high-quality cells starting from the small quantity (about 500,000 cells) of a tissue biopsy without the need of human intervention, thanks to a unique patented iterative process. Our product is at TRL 7; its performances, in terms of quality and costs, are superior to any competitor commercially available. We have developed the Facer over the course of 5 years thanks to cash investments of over €3 million. In the Phase 2 project we will finalise the product, perform a validation with external partners, gain the CE marking (our product is not a medical device), and find a distributor and a launching customer. We will initially tackle the European market to then expand globally once that the local regulatory barriers are overcome. In 2024, after 5 years from the first sale, our turnover will surpass the €60 million and our EBITDA will be over €36 million. Our innovation can enable affordable cell therapies at a large scale and change the life of millions of patients who suffer from diseases that have been deemed 'incurable' so far.

 Publications

year authors and title journal last update
List of publications.
2019 Mireia Ruiz
Development of an autonomous platform for CAR T-cell manufacturing
published pages: , ISSN: , DOI:
National Instrument case – Real world applications 2020-04-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FACER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FACER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

Cortx (2019)

Intelligent debt recovery platform.

Read More